This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
FAQ
- Which patients should be tested for PNH?
- How should I set up my flow cytometer for PNH testing?
- My instrument is only capable of 3 colours. Can I still perform high-quality PNH testing?
- In what buffer should blood be collected and how should it be kept before PNH testing?
- How long can a blood sample be kept before PNH testing?
- How should samples be transferred to referral laboratories?
- Can I use bone marrow for PNH testing and diagnosis?
- Is it sufficient to test only RBCs when trying to detect PNH?
- Why test on monocytes?
- Should I perform PNH testing on lymphocytes?
- How many cells should I acquire when testing for PNH?
- Should I wash cells following incubation with monoclonal antibodies?
- What are the recommended monoclonal antibodies (clones) and conjugates for the detection of PNH RBC and WBC clones?
- What are the recommended gating antibodies for WBCs?
- I think I am getting false negatives when testing for PNH. What might be causing this?
- I am getting false positives when testing for PNH. What might be causing this?
- How should I validate my own PNH assay?
- How often should a patient’s PNH cell population be monitored by flow cytometry?
- What is the difference between high-sensitivity and routine PNH testing?
- What is my PNH-testing sensitivity?
- How should I report the detection of only a few PNH cells? Does it mean that I have diagnosed a PNH patient?
- If PNH type II RBCs are detected in the absence of PNH neutrophils or monocytes, should this be reported as a PNH clone?
- If a patient has dysplasia or aplastic anaemia, does this affect PNH testing?
In this section:
RESOURCES TESTING RESOURCES USEFUL PUBLICATIONS GLOSSARY CASE STUDIES LINKS DOT-PLOT CHALLENGE-
References
- Borowitz MJ et al. Cytometry B Clin Cytom 2010; 78B: 211-230.
- Brodsky RA. Blood Rev 2008; 22: 65-74.
- Brodsky R. In: R. Hoffman et al, eds. Hematology: Basic Principles and Practices. 4th ed. Philadelphia, PA: Elsevier Churchill Livingstone; 2005: 419-427.
- Rother RP et al. JAMA 2005; 293: 1653-1662.
- Hillmen P et al. Am J Hematol 2010; 85: 553-559.
- Rachidi S et al. Eur J Intern Med 2010; 21: 260-267.
- Kelly R et al. Ther Clin Risk Manag 2009; 5: 911-921.
- Hill A et al. Br J Haematol 2007; 137: 181-192.
- Hillmen P et al. Blood 2007; 110: 4123-4128.
- Adams T et al. Dig Dis Sci 2002; 47: 58-64.
- Rosse WF. In: Hoffman R et al, eds. Hematology: Basic Principles and Practice. 3rd ed. New York, NY: Churchill Livingstone; 2000: 331-342.
- Rother RP et al. Nat Biotechnol 2007; 25: 1256-1264. [Published correction appears in Nat Biotechnol 2007; 25: 1488].
- Hillmen P et al. N Engl J Med 1995; 333: 1253-1258.
- Hill A et al. Blood 2013; 121: 4985-4996.
- Socié G et al; for the French Society of Haematology. Lancet 1996; 348: 573-577.
- Dacie JV, Lewis SM. Ser Haematol 1972; 5: 3-23.
- Nishimura J-I et al. Medicine 2004; 83: 193-207.
- Lee JW et al. Int J Hematol 2013; 97: 749-757.
- Brodsky RA. Blood 2014; 124: 2804-2811.
- Thomason et al Am J Clin Pathol 2014; 122: 128-134.
- Killick SB et al. Br J Haematol 2016; 172: 187-207.
- Illingworth A et al. Cytometry B Clin Cytom 2018; 94: 49-66.
- Dezern AE, Borowitz MJ. Cytometry B Clin Cytom 2018; 94: 16-22.
- Sutherland DR et al. Cytometry B Clin Cytom 2018; 94: 23-48.
- Oldaker T et al. Cytometry B Clin Cytom 2018; 94: 67-81.
- Sutherland DR et al. Cytometry B Clin Cytom 2012; 82B: 195-208.
- Marinov I et al. Cytometry B Clin Cytom 2013; 84: 229-236.
- Movalia MK et al. 17th Annual Meeting of the European Hematology Association, Amsterdam, the Netherlands, 14-17 June 2012, poster 0886.